CBD and dermatitis in dogs
Objective: to examine the effects of CBD without THC as a supplemental treatment for canine atopic dermatitis (CAD), as well as its adverse effects, and effects on concurrent drug use in dogs.
Design: retrospective case series
Sample: 8 dogs with CAD were diagnosed by veterinary dermatologists certified by the Japanese Society of Veterinary Dermatology.
Procedure: The medical records of dogs supplemented with CBD were evaluated with respect to signalment, physical examination, plasma C-reactive protein concentrations, pharmacologic management, the CAD Extent and Severity Index (4th iteration), and the Pruritus Visual Analog Scale.
Findings:
-
CBD used as a supplement in combination with other drugs, was well-tolerated over a wide dose range and decreased the occurrence of pruritus in dogs with CAD when ingested twice a day.
-
the use of CBD in combination with current CAD treatments suggested the possibility of reducing the dose of concomitant medications while increasing their efficacy.
Aim: To determine if CBD/CBDA is an effective therapy for canine atopic dermatitis (cAD).
Sample: 32 privately owned dogs with cAD.
Design: Prospective, randomised, double-blinded, placebo-controlled study.
Intervention:
-
Dogs were randomly assigned to receive either 2 mg/kg of an equal mix of CBD/CBDA (n = 17) or placebo for 4 weeks.
-
On Day (D)0, D14 and D28, Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04) and pruritus Visual Analog Scale (pVAS) scores were determined by investigators and owners, respectively.
-
Complete blood count, serum biochemistry profiles and cytokine bioassays were performed on serum collected on D0 and D28.
Product: 50:50 mix of CBD/CBDA in a sesame oil base (30 mg/ml CBD, 31 mg/ml CBDA, 1.2 mg THC and 1.3 mg/ml THCA). Capsules in 5, 10, 20 and 30 mg/ml CBD/CBDA increments for dosing.
Dogs were administered CBD/CBDA (approximately 2 mg/kg) or placebo, twice daily with a meal for the entire study period of 28 days.
Findings:
-
There was no significant difference in Canine Atopic Dermatitis Extent and Severity Index from D0 to D14 (p = 0.42) or D28 (p = 0.51) in either group.
-
pruritus Visual Analog Scale (pVAS) scores were significantly lower for the CBD group at D14 and D28 (p = 0.01) and a significant change in pruritus Visual Analog Scale (pVAS) from baseline was seen at D14 and not D28 between groups - even though there was a positive trend.
-
There was no significant difference in serum levels of interleukin (IL)-6, IL-8, monocyte chemoattractant protein - 1, IL-31 or IL-34 between groups at D0 or D28.
-
Elevated ALP was observed in four of 17 treatment group dogs.
Aim: to determine the influence of CBD on the daily activity of adult dogs.
Method:
-
24 dogs of various mixed breeds, research animals
-
Design: randomized complete block design
-
treatments targeted at 0 and 2.5mg (LOW) and at 5.0mg (HIGH) CBD/kg body weight (BW) per day split between two treats administered after twice-daily exercise
Findings:
-
CBD tended (P = 0.071) to reduce total daily scratching compared with the control.
-
CBD reduced scratching compared with control (P = 0.030).